KDA GROUP ANNOUNCES PARTNERSHIP AGREEMENT WITH CHU DE QUÉBEC-UNIVERSITÉ LAVAL FOR THE DEPLOYMENT OF MEDHERIZE

About this update from Kda Group Inc.

[{"type":"text","content":"\n\n\nKDA GROUP ANNOUNCES PARTNERSHIP AGREEMENT WITH CHU DE QUÉBEC-UNIVERSITÉ LAVAL FOR THE DEPLOYMENT OF MEDHERIZE\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\nTHETFORD MINES, QC, Dec. 3, 2025 /CNW/ - KDA Group Inc. (TSXV: KDA) (\"KDA\" or the \"Corporation\"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the signing of a partnership and collaboration agreement with the Centre hospitalier universitaire de Québec, Université Laval (\"CHU de Québec\") for the deployment of its Medherize platform at Hôpital du Saint-Sacrement, one of the CHU de Québec's five hospital facilities.\n\n\n\n\n\n\n\nThe Medherize platform is already implemented at Hôpital du Saint-Sacrement. This partnership aims to support breast cancer patients undergoing complex oral treatments, whose follow-up and coordination require close collaboration between hospital teams and community pharmacists. It will also serve as a springboard for expanding the solution to other hospital centers across Quebec, then throughout Canada, and eventually internationally.\nMedherize enables real-time therapeutic monitoring through the integration of clinical data, including information from the Dossier Santé Québec (DSQ), and validated clinical protocols that automate the management of adverse effects. The platform provides care teams with a shared and continuous view of each patient's treatment journey, improving coordination and overall care efficiency.\nThe solution will soon extend beyond breast oncology to encompass a broader range of complex treatments and specialty medications, including biotherapies, additional oncology therapies, as well as treatments for autoimmune and rare genetic diseases.\n\"Our Medherize solution is designed to support healthcare professionals in delivering optimized and personalized treatments while enhancing patients' quality of life,\" said Marc Lemieux, Chief Executive Officer and Chairman of the Board of KDA.\nDr. Julien Clément, Director of Professional ...

More updates from Kda Group Inc.